(Q37454026)

20 August 2017

Class-sparing regimens for initial treatment of HIV-1 infection (English)

1 reference

20 August 2017

0 references

Robert L Murphy

12

0 references

Diane Havlir

14

object named as

Diane Havlir

1 reference

20 August 2017

William G Powderly

5

0 references

Susan Swindells

13

object named as

Susan Swindells

1 reference

20 August 2017

Sharon A Riddler

1

1 reference

20 August 2017

Richard Haubrich

2

1 reference

20 August 2017

A Gregory DiRienzo

3

1 reference

20 August 2017

Lynne Peeples

4

1 reference

20 August 2017

Karin L Klingman

6

1 reference

20 August 2017

Kevin W Garren

7

1 reference

20 August 2017

Tania George

8

1 reference

20 August 2017

James F Rooney

9

1 reference

20 August 2017

Barbara Brizz

10

1 reference

20 August 2017

Umesh G Lalloo

11

1 reference

20 August 2017

John W Mellors

15

1 reference

20 August 2017

AIDS Clinical Trials Group Study A5142 Team

16

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

The New England Journal of Medicine

20 August 2017

1 reference

20 August 2017

358

1 reference

20 August 2017

2095-2106

1 reference

20 August 2017

20

1 reference

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Update of the drug resistance mutations in HIV-1: Fall 2006.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885902

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18480202

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CP

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18480202

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA074609

1 reference

20 August 2017

1 reference

20 August 2017

1 reference